Clinical Trial Update: A Study of NE3107 in Early Parkinson's [Phase 2]

View source ↗

Summary

A Phase 2 study of NE3107 for early Parkinson's disease is currently recruiting. Sponsored by BioVie Inc., the trial is enrolling participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NE3107 (NE3107)

Snippet

Sponsor: BioVie Inc. | Conditions: Parkinsons Disease (PD) | Phase 2 | Status: RECRUITING